Improvement of the Effectiveness of HER2+ Cancer Therapy by Use of Doxorubicin and Trastuzumab Modified Radioactive Gold Nanoparticles

[Image: see text] In the present article, we describe a multimodal radiobioconjugate that contains a chemotherapeutic agent (doxorubicin, DOX), a β-emitter ((198)Au), and a guiding vector (trastuzumab, Tmab) for targeted therapy of cancers overexpressing HER2 receptors. To achieve this goal, radioac...

Descripción completa

Detalles Bibliográficos
Autores principales: Żelechowska-Matysiak, Kinga, Salvanou, Evangelia-Alexandra, Bouziotis, Penelope, Budlewski, Tadeusz, Bilewicz, Aleksander, Majkowska-Pilip, Agnieszka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481397/
https://www.ncbi.nlm.nih.gov/pubmed/37607353
http://dx.doi.org/10.1021/acs.molpharmaceut.3c00414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481397/
https://www.ncbi.nlm.nih.gov/pubmed/37607353
http://dx.doi.org/10.1021/acs.molpharmaceut.3c00414

Ejemplares similares